Literature DB >> 10668879

Long-term results of subcutaneous parathyroid grafts in uremic patients.

P Kinnaert1, I Salmon, C Decoster-Gervy, A Vienne, L De Pauw, L Hooghe, C Tielemans.   

Abstract

HYPOTHESIS: Parathyroid glands are normally surrounded (entirely or partially) by fatty tissue. Subcutaneous parathyroid grafts are thus located in a normal environment. Therefore, we postulated that the late results of subcutaneous implantation of parathyroid tissue in uremic patients should be at least as good as those reported for intramuscular grafting. We also challenged the idea that the recurrence rate of renal hyperparathyroidism after surgery depended solely on the type of hyperplasia (diffuse vs nodular) observed in the implanted tissue.
DESIGN: A retrospective study of a series of patients without loss to follow-up.
SETTING: A university hospital and 9 affiliated dialysis units. PATIENTS AND
INTERVENTIONS: Fifty-nine patients (33 women and 26 men) operated on for renal hyperparathyroidism underwent the resection of at least 4 parathyroid glands followed by presternal subcutaneous implantation of parathyroid tissue. They were followed up for 12 to 130 months (median, 38 months). MAIN OUTCOME MEASURES: Failure of treatment, recurrence of disease, and hypoparathyroidism.
RESULTS: During the study period, 9 patients had to undergo another operation: 2 (3%) for persistent hyperparathyroidism due to a fifth ectopic gland and 7 (12%) for recurrence of hyperparathyroidism resulting from hypertrophy of the subcutaneous grafts. Four patients received a kidney transplant. The prevalence of hypoparathyroidism (intact parathyroid hormone serum level <1.6 pmol/L with a normal or low serum calcium concentration) was 14% (8 of 59 patients), and the curve representing the distribution of intact parathyroid hormone serum concentrations among operated on patients was shifted to the left when compared with the curve of patients who underwent hemodialysis and who had no indication for parathyroid surgery. In this latter group, the peak of the curve was situated between 1 and 2 times the upper normal limit, while it was in the normal range 12 to 130 months after total parathyroidectomy and subcutaneous parathyroid autotransplantation. No relation was observed between the recurrence rate of the disease and the histological characteristics of the parathyroid grafts. Also, their function was not influenced by the presence or absence of aluminum deposits in bone biopsy specimens that were obtained at the time of cervical exploration.
CONCLUSIONS: The late results of total parathyroidectomy and presternal subcutaneous grafting compare favorably with the published data on other surgical techniques proposed for the treatment of renal hyperparathyroidism. The ease with which the hypertrophied grafts are removed when the disease recurs warrants further use of this procedure.

Entities:  

Mesh:

Year:  2000        PMID: 10668879     DOI: 10.1001/archsurg.135.2.186

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  14 in total

1.  Initial parathyroid surgery in 606 patients with renal hyperparathyroidism.

Authors:  Ralph Schneider; Emily P Slater; Elias Karakas; Detlef K Bartsch; Katja Schlosser
Journal:  World J Surg       Date:  2012-02       Impact factor: 3.352

2.  Relevance of bilateral cervical thymectomy in patients with renal hyperparathyroidism: analysis of 161 patients undergoing reoperative parathyroidectomy.

Authors:  Ralph Schneider; Detlef K Bartsch; Katja Schlosser
Journal:  World J Surg       Date:  2013-09       Impact factor: 3.352

3.  Application of total parathyroidectomy with auto-transplantation for uremia secondary hyperparathyroidism treatment.

Authors:  Ying Jing; Hanhui Zhao; Yanming Ge; Fengyu Jia; Qingqing He; Suxia Wang; Jianzhong Meng
Journal:  Int J Clin Exp Med       Date:  2015-07-15

4.  Parathyroid autotransplantation in rats having hypoparathyroidism.

Authors:  Mehmet Erikoglu; Bayram Colak; Hatice Toy; Mehmet Gurbilek
Journal:  Int J Clin Exp Med       Date:  2015-09-15

5.  Intramuscular injection of parathyroid autografts is a viable option after total parathyroidectomy.

Authors:  Choon Chieh Tan; Wei Keat Cheah; Charles Tse Kuang Tan; Abu Rauff
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

6.  Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: A Simple and Effective Way to Avoid Hypoparathyroidism.

Authors:  Giuseppe Cavallaro; Olga Iorio; Marco Centanni; Natale Porta; Angelo Iossa; Lucilla Gargano; Susanna Del Duca; Angela Gurrado; Mario Testini; Vincenzo Petrozza; Gianfranco Silecchia
Journal:  World J Surg       Date:  2015-08       Impact factor: 3.352

7.  Feasibility of injectable thermoreversible gels for use in intramuscular injection of parathyroid autotransplantation.

Authors:  Hae Sang Park; Soo Yeon Jung; Ha Yeong Kim; Du Young Ko; Sung Min Chung; Byeongmoon Jeong; Han Su Kim
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-03-19       Impact factor: 2.503

8.  Parathyroid subcutaneous pre-sternal transplantation after parathyroidectomy for renal hyperparathyroidism. Long-term graft function.

Authors:  Miguel Echenique-Elizondo; José Antonio Amondarain; Fernando Vidaur; Carmen Olalla; Fernando Aribe; Adolfo Garrido; José Molina; Maria Teresa Rodrigo
Journal:  World J Surg       Date:  2007-05-22       Impact factor: 3.352

9.  Total parathyroidectomy and autotransplantation by the subcutaneous injection technique in secondary hyperparathyroidism.

Authors:  Jong Ho Yoon; Kee-Hyun Nam; Hang-Seok Chang; Woong Youn Chung; Cheong Soo Park
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

10.  Outcomes of Total Parathyroidectomy with Autotransplantation versus Subtotal Parathyroidectomy with Routine Addition of Thymectomy to both Groups: Single Center Experience of Secondary Hyperparathyroidism.

Authors:  Gürhan Sakman; Cem Kaan Parsak; Mustafa Balal; Gülşah Seydaoglu; Ismail Cem Eray; Gökhan Sarıtaş; Orhan Demircan
Journal:  Balkan Med J       Date:  2014-03-01       Impact factor: 2.021

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.